Dose dense 1 week on/1 week off temozolomide in recurrent glioma: A retrospective study

Journal of Neuro-Oncology

Volumn 108, Issue 1, 2012, Pages 195-200

  Taal, Walter ^a   Segers Van Rijn, Joyce M W ^a,b   Kros, Johan M ^a   Van Heuvel, Irene ^a   Van Der Rijt, Carin C D ^a   Bromberg, Jacoline E ^a   Sillevis Smitt, Peter A E ^a   Van Den Bent, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

Author keywords

19q; 1p; Astrocytoma; Brain tumors; Chemotherapy; Dose dense temozolomide; Glioblastoma; Glioma; Oligodendroglioma

Indexed keywords

NITROSOUREA; TEMOZOLOMIDE;

ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; GLIOMA; HUMAN; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PATIENT ASSESSMENT; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84860287212     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0832-5     Document Type: Article

References (30)

1. K Hoang-Xuan L Capelle M Kujas, et al. 2004 Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions J Clin Oncol 22 15 3133 3138 15284265 10.1200/JCO.2004.10.169 1:CAS:528:DC%2BD2cXpsVGrs7o%3D (Pubitemid 41103727)
2. van den Bent MJ, Carpentier AF, Brandes AA, et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for research and treatment of cancer phase III trial. J Clin Oncol 24(18):2715-2722 (Pubitemid 46630567)
3. W Taal HJ Dubbink CB Zonnenberg, et al. 2011 First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response Neuro Oncol 13 2 235 241 21177338 10.1093/neuonc/noq177 1:CAS:528:DC%2BC3MXisV2nsr8%3D
4. WK Yung MD Prados R Yaya-Tur, et al. 1999 Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 9 2762 2771 10561351 1:CAS:528:DyaK1MXmtlWru7s%3D (Pubitemid 29415233)
5. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma New Engl J Med 352 10 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
6. SL Gerson 2002 Clinical relevance of MGMT in the treatment of cancer J Clin Oncol 20 9 2388 2399 11981013 10.1200/JCO.2002.06.110 1:CAS:528: DC%2BD38XktVKrsL4%3D (Pubitemid 34441669)
7. ME Hegi AC Diserens T Gorlia, et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma New Engl J Med 352 10 997 1003 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
8. M Esteller J Garcia-Foncillas E Andion, et al. 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents New Engl J Med 343 19 1350 1354 11070098 10.1056/NEJM200011093431901 1:CAS:528:DC%2BD3cXosFOltLg%3D
9. AW Tolcher SL Gerson L Denis, et al. 2003 Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 7 1004 1011 12671695 10.1038/sj.bjc.6600827 1:CAS:528:DC%2BD3sXisFahtrY%3D (Pubitemid 36560766)
10. JR Perry K Belanger WP Mason, et al. 2010 Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study J Clin Oncol 28 12 2051 2057 20308655 10.1200/JCO.2009.26.5520 1:CAS:528: DC%2BC3cXmtlSksrk%3D
11. S Dall'oglio A D'Amico F Pioli, et al. 2008 Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas J Neurooncol 90 3 315 319 18688571 10.1007/s11060-008-9663-9
12. A Wick J Felsberg JP Steinbach, et al. 2007 Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma J Clin Oncol 25 22 3357 3361 17664483 10.1200/JCO.2007.10.7722 1:CAS:528:DC%2BD2sXhtVWqs7nO (Pubitemid 47325623)
13. JR Perry P Rizek R Cashman M Morrison T Morrison 2008 Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach Cancer 113 8 2152 2157 18756530 10.1002/cncr.23813 1:CAS:528:DC%2BD1cXht12lu77J
14. B Neyns C Chaskis E Joosens, et al. 2008 A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma Cancer Invest 26 3 269 277 18317968 10.1080/07357900701708393 1:CAS:528:DC%2BD1cXislalsrk%3D (Pubitemid 351329006)
15. HM Strik JH Buhk A Wrede, et al. 2008 Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas Mol Med Rep 1 6 863 867 1:CAS:528:DC%2BD1cXhtlGltr%2FF
16. AA Brandes A Tosoni G Cavallo, et al. 2006 Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) Br J Cancer 95 9 1155 1160 17024124 10.1038/sj.bjc.6603376 1:CAS:528:DC%2BD28XhtFChs73O (Pubitemid 44658477)
17. RB Khan JJ Raizer MG Malkin KA Bazylewicz LE Abrey 2002 A phase II study of extended low-dose temozolomide in recurrent malignant gliomas Neuro Oncol 4 1 39 43 11772431 1:CAS:528:DC%2BD38XktlGltL4%3D (Pubitemid 34269465)
18. N Pouratian J Gasco JH Sherman ME Shaffrey D Schiff 2007 Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas J Neurooncol 82 3 281 288 17082887 10.1007/s11060-006-9280-4 1:CAS:528:DC%2BD2sXlvF2ju7c%3D (Pubitemid 46614391)
19. MJ van den Bent JS Wefel D Schiff, et al. 2011 Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas Lancet Oncol 12 6 583 593 21474379 10.1016/S1470-2045(11)70057-2
20. PY Wen DR Macdonald DA Reardon, et al. 2010 Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 11 1963 1972 20231676 10.1200/JCO.2009.26.3541
21. M Brada K Hoang-Xuan R Rampling, et al. 2001 Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse Ann Oncol 12 2 259 266 11300335 10.1023/A:1008382516636 1:STN:280: DC%2BD3M3gvFamtg%3D%3D (Pubitemid 32223879)
22. WK Yung RE Albright J Olson, et al. 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 5 588 593 10944597 10.1054/bjoc.2000.1316 1:CAS:528: DC%2BD3cXmvVCgsrs%3D (Pubitemid 30636298)
23. AA Brandes M Ermani U Basso, et al. 2002 Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study Oncology 63 1 38 41 12187069 10.1159/000065718 1:CAS:528:DC%2BD38XmtlGitbk%3D (Pubitemid 34977935)
24. MJ van den Bent O Chinot W Boogerd, et al. 2003 Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972 Ann Oncol 14 4 599 602 12649108 10.1093/annonc/mdg157 (Pubitemid 41295090)
25. MC Kouwenhoven JM Kros PJ French, et al. 2006 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment Eur J Cancer 42 15 2499 2503 16914310 10.1016/j.ejca.2006. 05.021 1:CAS:528:DC%2BD28XhtVagtrfM (Pubitemid 44468379)
26. W Taal D Brandsma HG de Bruin, et al. 2008 Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide Cancer 113 2 405 410 18484594 10.1002/cncr.23562 1:CAS:528:DC%2BD1cXpt1Orsbs%3D
27. A Tosoni E Franceschi M Ermani, et al. 2008 Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas J Neurooncol 89 2 179 185 18431544 10.1007/s11060-008-9600-y 1:CAS:528:DC%2BD1cXhtFegu7zF
28. YB Su S Sohn SE Krown, et al. 2004 Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications J Clin Oncol 22 4 610 616 14726505 10.1200/JCO.2004.07.060 1:CAS:528: DC%2BD2cXpsVajs7s%3D (Pubitemid 41095063)
29. M Brada S Stenning R Gabe, et al. 2010 Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma J Clin Oncol 28 30 4601 4608 20855843 10.1200/JCO.2009.27.1932 1:CAS:528:DC%2BC3cXhsFaitLzP
30. MR Gilbert MH Wang KD Aldape, et al. 2011 Rtog 0525: a randomized phase III trial comparing standard adjuvant temozolomide (Tmz) with a dose-dense (Dd) schedule in newly diagnosed glioblastoma (Gbm) Neuro-Oncology 13 51 10.1093/neuonc/noq150